{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:39:03Z","timestamp":1790383143802,"version":"4.1.0"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T00:00:00Z","timestamp":1383609600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T00:00:00Z","timestamp":1383609600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"DOI":"10.1038\/ncomms3735","type":"journal-article","created":{"date-parts":[[2013,11,5]],"date-time":"2013-11-05T15:58:36Z","timestamp":1383667116000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":97,"title":["Selective cancer targeting with prodrugs activated by histone deacetylases and a tumour-associated protease"],"prefix":"10.1038","volume":"4","author":[{"given":"Nobuhide","family":"Ueki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole S.","family":"Sampson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael J.","family":"Hayman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2013,11,5]]},"reference":[{"key":"BFncomms3735_CR1","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.canlet.2008.08.016","volume":"277","author":"O Witt","year":"2009","unstructured":"Witt, O., Deubzer, H. E., Milde, T. & Oehme, I. HDAC family: what are the cancer relevant targets? Cancer Lett. 277, 8\u201321 (2009).","journal-title":"Cancer Lett."},{"key":"BFncomms3735_CR2","doi-asserted-by":"publisher","first-page":"7751","DOI":"10.1073\/pnas.0903139106","volume":"106","author":"M Haberland","year":"2009","unstructured":"Haberland, M., Johnson, A., Mokalled, M. H., Montgomery, R. L. & Olson, E. N. Genetic dissection of histone deacetylase requirement in tumor cells. Proc. Natl Acad. Sci. USA 106, 7751\u20137755 (2009).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms3735_CR3","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden, J. E., Peart, M. J. & Johnstone, R. W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov. 5, 769\u2013784 (2006).","journal-title":"Nat. Rev. Drug Discov."},{"key":"BFncomms3735_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/nrc1779","volume":"6","author":"S Minucci","year":"2006","unstructured":"Minucci, S. & Pelicci, P. G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 6, 38\u201351 (2006).","journal-title":"Nat. Rev. Cancer"},{"key":"BFncomms3735_CR5","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1002\/jcb.22185","volume":"107","author":"PA Marks","year":"2009","unstructured":"Marks, P. A. & Xu, W. S. Histone deacetylase inhibitors: Potential in cancer therapy. J. Cell Biochem. 107, 600\u2013608 (2009).","journal-title":"J. Cell Biochem."},{"key":"BFncomms3735_CR6","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1007\/s13148-010-0012-4","volume":"1","author":"JM Wagner","year":"2010","unstructured":"Wagner, J. M., Hackanson, B., Lubbert, M. & Jung, M. Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy. Clin. Epigenet. 1, 117\u2013136 (2010).","journal-title":"Clin. Epigenet."},{"key":"BFncomms3735_CR7","doi-asserted-by":"publisher","first-page":"14639","DOI":"10.1073\/pnas.1008522107","volume":"107","author":"JH Lee","year":"2010","unstructured":"Lee, J. H., Choy, M. L., Ngo, L., Foster, S. S. & Marks, P. A. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc. Natl Acad. Sci. USA 107, 14639\u201314644 (2010).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"BFncomms3735_CR8","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1016\/j.ccr.2010.10.022","volume":"18","author":"S Bhaskara","year":"2010","unstructured":"Bhaskara, S. et al. Hdac3 is essential for the maintenance of chromatin structure and genome stability. Cancer Cell 18, 436\u2013447 (2010).","journal-title":"Cancer Cell"},{"key":"BFncomms3735_CR9","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/S1535-6108(04)00111-4","volume":"5","author":"JA Joyce","year":"2004","unstructured":"Joyce, J. A. et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 5, 443\u2013453 (2004).","journal-title":"Cancer Cell"},{"key":"BFncomms3735_CR10","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1515\/BC.2004.132","volume":"385","author":"C Jedeszko","year":"2004","unstructured":"Jedeszko, C. & Sloane, B. F. Cysteine cathepsins in human cancer. Biol. Chem. 385, 1017\u20131027 (2004).","journal-title":"Biol. Chem."},{"key":"BFncomms3735_CR11","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.1038\/emboj.2011.225","volume":"30","author":"I Gonzalez-Suarez","year":"2011","unstructured":"Gonzalez-Suarez, I. et al. A new pathway that regulates 53BP1 stability implicates cathepsin L and vitamin D in DNA repair. EMBO J. 30, 3383\u20133396 (2011).","journal-title":"EMBO J."},{"key":"BFncomms3735_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1002\/ijc.20398","volume":"112","author":"J Collette","year":"2004","unstructured":"Collette, J., Ulku, A. S., Der, C. J., Jones, A. & Erickson, A. H. Enhanced cathepsin L expression is mediated by different Ras effector pathways in fibroblasts and epithelial cells. Int. J. Cancer 112, 190\u2013199 (2004).","journal-title":"Int. J. Cancer"},{"key":"BFncomms3735_CR13","first-page":"55","volume":"2","author":"DT Denhardt","year":"1987","unstructured":"Denhardt, D. T., Greenberg, A. H., Egan, S. E., Hamilton, R. T. & Wright, J. A. Cysteine proteinase cathepsin L expression correlates closely with the metastatic potential of H-ras-transformed murine fibroblasts. Oncogene 2, 55\u201359 (1987).","journal-title":"Oncogene"},{"key":"BFncomms3735_CR14","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1172\/JCI113497","volume":"81","author":"LJ Joseph","year":"1988","unstructured":"Joseph, L. J., Chang, L. C., Stamenkovich, D. & Sukhatme, V. P. Complete nucleotide and deduced amino acid sequences of human and murine preprocathepsin L. An abundant transcript induced by transformation of fibroblasts. J. Clin. Invest. 81, 1621\u20131629 (1988).","journal-title":"J. Clin. Invest."},{"key":"BFncomms3735_CR15","doi-asserted-by":"publisher","first-page":"7013","DOI":"10.1021\/ac200815q","volume":"83","author":"Y Tian","year":"2011","unstructured":"Tian, Y., Bova, G. S. & Zhang, H. Quantitative glycoproteomic analysis of optimal cutting temperature-embedded frozen tissues identifying glycoproteins associated with aggressive prostate cancer. Anal. Chem. 83, 7013\u20137019 (2011).","journal-title":"Anal. Chem."},{"key":"BFncomms3735_CR16","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1083\/jcb.201204053","volume":"200","author":"DA Grotsky","year":"2013","unstructured":"Grotsky, D. A. et al. BRCA1 loss activates cathepsin L-mediated degradation of 53BP1 in breast cancer cells. J. Cell Biol. 200, 187\u2013202 (2013).","journal-title":"J. Cell Biol."},{"key":"BFncomms3735_CR17","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1097-2765(04)00209-6","volume":"14","author":"B Goulet","year":"2004","unstructured":"Goulet, B. et al. A cathepsin L isoform that is devoid of a signal peptide localizes to the nucleus in S phase and processes the CDP\/Cux transcription factor. Mol. Cell 14, 207\u2013219 (2004).","journal-title":"Mol. Cell"},{"key":"BFncomms3735_CR18","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1158\/1541-7786.MCR-07-0160","volume":"5","author":"B Goulet","year":"2007","unstructured":"Goulet, B. et al. Increased expression and activity of nuclear cathepsin L in cancer cells suggests a novel mechanism of cell transformation. Mol. Cancer Res. 5, 899\u2013907 (2007).","journal-title":"Mol. Cancer Res."},{"key":"BFncomms3735_CR19","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.cell.2008.09.055","volume":"135","author":"EM Duncan","year":"2008","unstructured":"Duncan, E. M. et al. Cathepsin L proteolytically processes histone H3 during mouse embryonic stem cell differentiation. Cell 135, 284\u2013294 (2008).","journal-title":"Cell"},{"key":"BFncomms3735_CR20","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.lfs.2009.11.016","volume":"86","author":"JM Lankelma","year":"2010","unstructured":"Lankelma, J. M. et al. Cathepsin L, target in cancer treatment? Life Sci. 86, 225\u2013233 (2010).","journal-title":"Life Sci."},{"key":"BFncomms3735_CR21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.bbrc.2003.09.043","volume":"310","author":"KB Glaser","year":"2003","unstructured":"Glaser, K. B. et al. Role of class I and class II histone deacetylases in carcinoma cells using siRNA. Biochem. Biophys. Res. Commun. 310, 529\u2013536 (2003).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"BFncomms3735_CR22","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/S1535-6108(04)00114-X","volume":"5","author":"P Zhu","year":"2004","unstructured":"Zhu, P. et al. Induction of HDAC2 expression upon loss of APC in colorectal tumorigenesis. Cancer Cell 5, 455\u2013463 (2004).","journal-title":"Cancer Cell"},{"key":"BFncomms3735_CR23","doi-asserted-by":"publisher","first-page":"13548","DOI":"10.1074\/jbc.M510023200","volume":"281","author":"AJ Wilson","year":"2006","unstructured":"Wilson, A. J. et al. Histone deacetylase 3 (HDAC3) and other class I HDACs regulate colon cell maturation and p21 expression and are deregulated in human colon cancer. J. Biol. Chem. 281, 13548\u201313558 (2006).","journal-title":"J. Biol. Chem."},{"key":"BFncomms3735_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.7150\/thno.4068","volume":"2","author":"KY Choi","year":"2012","unstructured":"Choi, K. Y., Swierczewska, M., Lee, S. & Chen, X. Protease-activated drug development. Theranostics 2, 156\u2013178 (2012).","journal-title":"Theranostics"},{"key":"BFncomms3735_CR25","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1038\/sj.onc.1205577","volume":"21","author":"B Vecsey-Semjen","year":"2002","unstructured":"Vecsey-Semjen, B. et al. Novel colon cancer cell lines leading to better understanding of the diversity of respective primary cancers. Oncogene 21, 4646\u20134662 (2002).","journal-title":"Oncogene"},{"key":"BFncomms3735_CR26","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1101\/gad.10.19.2462","volume":"10","author":"M Oft","year":"1996","unstructured":"Oft, M. et al. TGF-beta1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev. 10, 2462\u20132477 (1996).","journal-title":"Genes Dev."},{"key":"BFncomms3735_CR27","doi-asserted-by":"crossref","first-page":"17174","DOI":"10.1016\/S0021-9258(17)44885-X","volume":"265","author":"M Yoshida","year":"1990","unstructured":"Yoshida, M., Kijima, M., Akita, M. & Beppu, T. Potent and specific inhibition of mammalian histone deacetylase both in vivo and in vitro by trichostatin A. J. Biol. Chem. 265, 17174\u201317179 (1990).","journal-title":"J. Biol. Chem."},{"key":"BFncomms3735_CR28","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1053\/gast.2001.22472","volume":"120","author":"JM Mariadason","year":"2001","unstructured":"Mariadason, J. M., Velcich, A., Wilson, A. J., Augenlicht, L. H. & Gibson, P. R. Resistance to butyrate-induced cell differentiation and apoptosis during spontaneous Caco-2 cell differentiation. Gastroenterology 120, 889\u2013899 (2001).","journal-title":"Gastroenterology"},{"key":"BFncomms3735_CR29","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/S1074-5521(02)00305-8","volume":"10","author":"D Wegener","year":"2003","unstructured":"Wegener, D., Wirsching, F., Riester, D. & Schwienhorst, A. A fluorogenic histone deacetylase assay well suited for high-throughput activity screening. Chem. Biol. 10, 61\u201368 (2003).","journal-title":"Chem. Biol."},{"key":"BFncomms3735_CR30","doi-asserted-by":"publisher","first-page":"3441","DOI":"10.1158\/1078-0432.CCR-07-4427","volume":"14","author":"C Bonfils","year":"2008","unstructured":"Bonfils, C. et al. Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay. Clin. Cancer Res. 14, 3441\u20133449 (2008).","journal-title":"Clin. Cancer Res."},{"key":"BFncomms3735_CR31","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1042\/BJ20070779","volume":"409","author":"N Khan","year":"2008","unstructured":"Khan, N. et al. Determination of the class and isoform selectivity of small-molecule histone deacetylase inhibitors. Biochem. J. 409, 581\u2013589 (2008).","journal-title":"Biochem. J."},{"key":"BFncomms3735_CR32","doi-asserted-by":"publisher","first-page":"6841","DOI":"10.1158\/1078-0432.CCR-09-0547","volume":"15","author":"J Arts","year":"2009","unstructured":"Arts, J. et al. JNJ-26481585, a novel \u2018second-generation\u2019 oral histone deacetylase inhibitor, shows broad-spectrum preclinical antitumoral activity. Clin. Cancer Res. 15, 6841\u20136851 (2009).","journal-title":"Clin. Cancer Res."},{"key":"BFncomms3735_CR33","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1038\/embor.2009.88","volume":"10","author":"A Nebbioso","year":"2009","unstructured":"Nebbioso, A. et al. Selective class II HDAC inhibitors impair myogenesis by modulating the stability and activity of HDAC-MEF2 complexes. EMBO Rep. 10, 776\u2013782 (2009).","journal-title":"EMBO Rep."},{"key":"BFncomms3735_CR34","doi-asserted-by":"publisher","first-page":"4617","DOI":"10.1093\/nar\/14.11.4617","volume":"14","author":"JA Vara","year":"1986","unstructured":"Vara, J. A., Portela, A., Ortin, J. & Jimenez, A. Expression in mammalian cells of a gene from Streptomyces alboniger conferring puromycin resistance. Nucleic Acids Res. 14, 4617\u20134624 (1986).","journal-title":"Nucleic Acids Res."},{"key":"BFncomms3735_CR35","doi-asserted-by":"crossref","first-page":"6895","DOI":"10.1016\/S0021-9258(19)44669-3","volume":"247","author":"S Pestka","year":"1972","unstructured":"Pestka, S., Rosenfeld, H., Harris, R. & Hintikka, H. Studies on transfer ribonucleic acid-ribosome complexes. XXI. Effect of antibiotics on peptidyl-puromycin synthesis by mammalian polyribosomes. J. Biol. Chem. 247, 6895\u20136900 (1972).","journal-title":"J. Biol. Chem."},{"key":"BFncomms3735_CR36","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1038\/nmeth.1314","volume":"6","author":"EK Schmidt","year":"2009","unstructured":"Schmidt, E. K., Clavarino, G., Ceppi, M. & Pierre, P. SUnSET, a nonradioactive method to monitor protein synthesis. Nat. Methods 6, 275\u2013277 (2009).","journal-title":"Nat. Methods"},{"key":"BFncomms3735_CR37","doi-asserted-by":"publisher","first-page":"6958","DOI":"10.1021\/jm901181h","volume":"52","author":"DM Bender","year":"2009","unstructured":"Bender, D. M. et al. Synthesis, crystallization, and biological evaluation of an orally active prodrug of gemcitabine. J. Med. Chem. 52, 6958\u20136961 (2009).","journal-title":"J. Med. Chem."},{"key":"BFncomms3735_CR38","doi-asserted-by":"publisher","first-page":"927","DOI":"10.1211\/jpp.58.7.0007","volume":"58","author":"EP Cheon","year":"2006","unstructured":"Cheon, E. P., Hong, J. H. & Han, H. K. Enhanced cellular uptake of Ara-C via a peptidomimetic prodrug, L-valyl-ara-C in Caco-2 cells. J. Pharm. Pharmacol. 58, 927\u2013932 (2006).","journal-title":"J. Pharm. Pharmacol."},{"key":"BFncomms3735_CR39","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s11307-012-0561-3","volume":"15","author":"S Eigner","year":"2013","unstructured":"Eigner, S. et al. Imaging of protein synthesis: in vitro and in vivo evaluation of (44)Sc-DOTA-puromycin. Mol. Imaging Biol. 15, 79\u201386 (2013).","journal-title":"Mol. Imaging Biol."},{"key":"BFncomms3735_CR40","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1016\/j.chembiol.2004.05.011","volume":"11","author":"SR Starck","year":"2004","unstructured":"Starck, S. R., Green, H. M., Alberola-Ila, J. & Roberts, R. W. A general approach to detect protein expression in vivo using fluorescent puromycin conjugates. Chem. Biol. 11, 999\u20131008 (2004).","journal-title":"Chem. Biol."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/ncomms3735.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms3735","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/ncomms3735.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,6]],"date-time":"2023-01-06T01:13:58Z","timestamp":1672967638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/ncomms3735"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11,5]]},"references-count":40,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2013,12,20]]}},"alternative-id":["BFncomms3735"],"URL":"https:\/\/doi.org\/10.1038\/ncomms3735","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,11,5]]},"assertion":[{"value":"17 April 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"N.U. and M.J.H. are co-inventors on a pending patent application entitled \u2018Novel prodrugs for selective anticancer therapy\u2019 (PCT\/US2013\/060443). All other authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2735"}}